Pediatric Neurology
Volume 28, Issue 5 , Pages 382-384 , May 2003

Reversible altered consciousness with brain atrophy caused by valproic acid

  • Hideo Yamanouchi, MD

      Affiliations

    • Department of Pediatrics, Dokkyo University School of Medicine, Tochigi, Japan
    • Corresponding Author InformationCommunications should be addressed to: Dr. Yamanouchi; Department of Pediatrics, Dokkyo University School of Medicine; 880 Kitakobayashi; Mibu, Shimotsuga;Tochigi 321-0293, Japan.
    • ,
  • Takako Ota, MD

      Affiliations

    • Department of Pediatrics, Shimotsuga General Hospital, Tochigi, Japan
    • ,
  • George Imataka, MD

      Affiliations

    • Department of Pediatrics, Shimotsuga General Hospital, Tochigi, Japan
    • ,
  • Eiji Nakagawa, MD

      Affiliations

    • Department of Pediatrics, Dokkyo University School of Medicine, Tochigi, Japan
    • ,
  • Mitsuoki Eguchi, MD

      Affiliations

    • Department of Pediatrics, Dokkyo University School of Medicine, Tochigi, Japan

Received 25 July 2002 ,Accepted 10 December 2002.

References 

  1. Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A. Hyperamonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase. J Neurol Neurosurg Psychiatry. 1998;64:680–682
  2. Kifune A, Kubota F, Shibata N, Akata T, Kikuchi S. Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia. 2000;41:909–912
  3. McLachlan RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci. 1987;14:294–296
  4. Papazian O, Canizales E, Alfonso I, Archila R, Duchowny M, Aicardi J. Reversible dementia and apparent brain atrophy during valproate therapy. Ann Neurol. 1995;38:687–691
  5. Guerrini R, Belmonte A, Canapicchi R, Casalini C, Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia. 1998;39:27–32
  6. Lam CW, Lau CH, Williams JC, Chan Y, Wong LJ. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr. 1997;156:562–564
  7. Chabrol B, Mancini J, Chretien D, Rstin P, Munnich A, Pinsard N. Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Paediatr. 1994;153:133–135
  8. Triggs WJ, Gilmore RL, Millington DS, Cibula J, Bunch TS, Harman E. Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. Int J Clin Pharmacol Ther. 1997;35:353–356
  9. Marescaux C, Warter JM, Micheletti G, Rumbach L, Coquillat G, Kurtz D. Stuporous episodes during treatment with sodium valproate (Report of seven cases). Epilepsia. 1982;23:297–305
  10. Armon C, Shin C, Miller P, et al.  Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology. 1996;47:626–635

PII: S0887-8994(03)00005-5

doi: 10.1016/S0887-8994(03)00005-5

Pediatric Neurology
Volume 28, Issue 5 , Pages 382-384 , May 2003

Article Tools

* Image Usage & Resolution